» Articles » PMID: 38339236

Digitally Enhanced Methods for the Diagnosis and Monitoring of Treatment Responses in Actinic Keratoses: A New Avenue in Personalized Skin Care

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Feb 10
PMID 38339236
Authors
Affiliations
Soon will be listed here.
Abstract

Non-melanocytic skin cancers represent an important public health problem due to the increasing incidence and the important local destructive potential. Thus, the early diagnosis and treatment of precancerous lesions (actinic keratoses) is a priority for the dermatologist. In recent years, non-invasive skin imaging methods have seen an important development, moving from simple observational methods used in clinical research, to true diagnostic and treatment methods that make the dermatologist's life easier. Given the frequency of these precancerous lesions, their location on photo-exposed areas, as well as the long treatment periods, with variable, imprecise end-points, the need to use non-invasive imaging devices is increasingly evident to complete the clinical observations in the diagnosis and treatment of these lesions, with the aim of increasing accuracy and decreasing the adverse effects due to long treatment duration. This is the first review that brings together all skin imaging methods (dermoscopy, reflectance confocal microscopy, ultrasonography, dermoscopy-guided high frequency ultrasonography, and optical coherence tomography) used in the evaluation of actinic keratoses and their response to different treatment regimens.

Citing Articles

Automatic Assessment of AK Stage Based on Dermatoscopic and HFUS Imaging-A Preliminary Study.

Korecka K, Slian A, Polanska A, Danczak-Pazdrowska A, Zaba R, Czajkowska J J Clin Med. 2025; 13(24.

PMID: 39768422 PMC: 11677879. DOI: 10.3390/jcm13247499.


Vascular Characteristics of Treatment-resistant and -responsive Actinic Keratosis Identified with Dynamic Optical Coherence Tomography.

Fredman G, Haedersdal M, Philipsen P, Andersen F, Bjerring P, Wiegell S Acta Derm Venereol. 2024; 104:adv42190.

PMID: 39585185 PMC: 11609724. DOI: 10.2340/actadv.v104.42190.


Skin lesion segmentation using deep learning algorithm with ant colony optimization.

Sarwar N, Irshad A, Naith Q, D Alsufiani K, Almalki F BMC Med Inform Decis Mak. 2024; 24(1):265.

PMID: 39334181 PMC: 11428829. DOI: 10.1186/s12911-024-02686-x.

References
1.
Ulrich M, Zalaudek I, Welzel J . Shining into the White: The Spectrum of Epithelial Tumors from Actinic Keratosis to Squamous Cell Carcinoma. Dermatol Clin. 2016; 34(4):459-467. DOI: 10.1016/j.det.2016.05.008. View

2.
Swanson N, Cognata Smith C, Kaur M, Goldenberg G . Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol. 2013; 12(11):1278-82. View

3.
Campione E, Rivieccio A, Shumak R, Costanza G, Cosio T, Lambiase S . Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses. Pharmaceuticals (Basel). 2023; 16(12). PMC: 10748142. DOI: 10.3390/ph16121686. View

4.
Ulrich M, Stockfleth E, Roewert-Huber J, Astner S . Noninvasive diagnostic tools for nonmelanoma skin cancer. Br J Dermatol. 2007; 157 Suppl 2:56-8. DOI: 10.1111/j.1365-2133.2007.08275.x. View

5.
Markham A, Duggan S . Tirbanibulin: First Approval. Drugs. 2021; 81(4):509-513. DOI: 10.1007/s40265-021-01479-0. View